In this interview from the 2025 American Academy of Allergy, Asthma, & Immunology (AAAAI) annual meeting, Joseph Han, MD, from Eastern Virginia Medical School, discusses the phase 3 WAYPOINT trial findings on tezepelumab for chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated a 92% reduction in the need for nasal polyp surgery among patients receiving tezepelumab compared with placebo, along with significant improvements in nasal congestion, sense of smell, and quality-of-life measures. Han provides insight into the clinical implications of these findings and the next steps in CRSwNP research. Timestamps: 00:007: Key findings of phase 3 WAYPOINT trial on tezepelumab for nasal polyp 02:42: Tezepelumab vs other biologics 03:37: Tezepelumab’s mechanism of action 05:06: Safety findings 06:36: Next steps for tezepelumab Watch the full interview for an expert perspective on how tezepelumab may reshape treatment approaches for patients with severe CRSwNP. #Tezepelumab #CRSwNP #AAAAI25 #NasalPolyps